Sun Pharmaceutical Industries, an international, integrated, speciality pharmaceutical company, on Thursday announced the U.S. launch of the website for its long-term care (LTC) division, www.sunltc.com. The new website presents Sun Pharma's LTC portfolio of alternative formulation products and underscores Sun Pharma's commitment to meeting the needs of the up to 40% of American adults who cannot or will not swallow solid medication forms.

Sun Pharma's LTC portfolio includes the first and only U.S. Food and Drug Administration (FDA)-approved extended-release sprinkle formulation of metoprolol succinate; the first and only FDAapproved sprinkle formulation of delayed-release duloxetine; and the first and only approved sprinkle formulation of rosuvastatin,

Ezallor Sprinkle (rosuvastatin) immediate-release capsules. The Ezallor Sprinkle label was recently updated to allow for sprinkling the capsule contents over pudding (in addition to applesauce) as a soft-food alternative mode of administration.

"Through this website, Sun Pharma aims to call attention to the broad need for our three alternative sprinkle formulations of widely prescribed medications, which are designed for those who cannot or will not swallow solid medication forms," said Mark Hagler, Senior Vice President and Head of Ophthalmics, Oncology and LTC at Sun Pharma.

Shares of the company gained Rs 7.15, or 1.19%, to settle at  Rs 609.70.  The total volume of shares traded  was 701,272 at the BSE (Thursday).